Abstract:Background: Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human GAA gene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand. Methods: Twelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients, GAA gene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool. Results: All patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or < 1% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C > G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G > A (p.Asp513Gly), c.1895 T > G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G > A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class "B" and p. Ala261Thr as class "D" or "E". These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain. Conclusions: The present study provides useful information on the mutations of GAA gene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.

New Gaa Mutations In Japanese Patients With Gsdii (Pompe Disease)

Identification of Eight Novel Mutations of the Acid Α-Glucosidase Gene Causing the Infantile or Juvenile Form of Glycogen Storage Disease Type II

Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease

[Clinical Features and Acid Alpha-Glucosidase Gene Mutation in 7 Chinese Patients with Glycogen Storage Disease Type II].

Mutations in GAA Gene in Tunisian Families with Infantile Onset Pompe Disease: Novel Mutation and Structural Modeling Investigations

Three novel mutations of the G6PC gene identified in Chinese patients with glycogen storage disease type Ia

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease

Clinical and GAA Gene Mutation Analysis in Mainland Chinese Patients with Late-Onset Pompe Disease: Identifying C.2238g > C As the Most Common Mutation

Development of a feasible assay for the detection of GAA mutations in patients with Pompe disease

Molecular genetics of glycogen-storage disease type 1a in Chinese patients of Taiwan

Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia

[Clinical characteristics and GAA gene mutation in children with glycogen storage disease type II: an analysis of 3 cases].

Pathological features of glycogen storage disease type II highlighted in the knockout mouse model

Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand

Molecular Approaches for the Treatment of Pompe Disease

[AGL gene analysis of a pedigree with glycogen storage disease type III and identification of a novel mutation]

Clinical and Functional Characterization of Novel AGL Variants in Two Families with Glycogen Storage Disease Type III

Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China

Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III

Three novel SLC37A4 variants in glycogen storage disease type 1b and a literature review